BLA 761452 · Accord Biopharma Inc.
Immgolis
Golimumab-Sldi · Solution
Last checked: Nov 20, 2026Latest source record: May 15, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2026
May 15, 2026
Approved uses
1
Original approval plus efficacy supplements
Registered trials
110
40 Phase 3, 8 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 15, 2026 Original approval · Type 5 - New Formulation or New Manufacturer LabelLetterMedication Guide
3 products under this application
- IMMGOLIS · GOLIMUMAB-SLDI 100MG/1ML · INJECTION, SOLUTION · Prescription
- IMMGOLIS INTRI · GOLIMUMAB-SLDI 50MG/4ML · INJECTION, SOLUTION · Prescription
- IMMGOLIS · GOLIMUMAB-SLDI 50MG/0.5ML · INJECTION, SOLUTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Golimumab" as an intervention, any sponsor and status, largest first.
- Subcutaneous Golimumab (GLM) Plus DMARDs for Rheumatoid Arthritis, Followed by Intravenous/Subcutaneous GLM Strategy (P06129 AM2)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT00975130 · 3,366 participants · Start Sep 2009 · Primary completion Aug 2011
Drug: SC golimumab; IV golimumab · For: Arthritis, Rheumatoid
- An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative ColitisPivotal-lookingCompleted
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT00488631 · 1,228 participants · Start Sep 2007 · Primary completion Oct 2011
Drug: Placebo; Golimumab 50 mg and 2 more · For: Colitis, Ulcerative
Sites: Birmingham, Alabama; Little Rock, Arkansas; Anaheim, California · 297 sites in all
- An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative ColitisPivotal-lookingCompleted
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT00487539 · 1,065 participants · Start Aug 2007 · Primary completion Oct 2010
Drug: Placebo; Golimumab 100 mg and 3 more · For: Colitis, Ulcerative
Sites: Birmingham, Alabama; Little Rock, Arkansas; Roseville, California · 200 sites in all
- COVID-19 VaccinE Response in Rheumatology PatientsPivotal-lookingCompleted
Jeffrey CurtisAcademic, hospital or other
NCT05080218 · 841 participants · Start Nov 15, 2021 · Primary completion Apr 4, 2024
Drug: Upadacitinib; Abatacept and 6 more · For: Rheumatoid Arthritis; Psoriatic Arthritis; Spondylarthritis
Sites: Birmingham, Alabama; Hoover, Alabama; Phoenix, Arizona · 8 sites in all
- Comparative Study of BAT2506 With Simponi® in Participants With Active Psoriatic ArthritisPivotal-lookingCompleted
Bio-Thera SolutionsIndustry
NCT05046431 · 704 participants · Start May 6, 2021 · Primary completion Oct 6, 2023
Drug: BAT2506; EU Simponi · For: Psoriatic Arthritis
Sites: Chengdu, China
- A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's DiseasePivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT05242471 · 703 participants · Start Jul 22, 2022 · Primary completion May 23, 2025
Drug: Guselkumab; Golimumab and 2 more · For: Crohn's Disease
Sites: Birmingham, Alabama; Tucson, Arizona; Little Rock, Arkansas · 456 sites in all
- Determination of the Optimal Treatment Target in Ulcerative ColitisPivotal-lookingCompleted
Alimentiv Inc.Academic, hospital or other
NCT04259138 · 672 participants · Start Feb 18, 2020 · Primary completion Apr 13, 2026
Drug: Treatment Algorithm A; Treatment Algorithm B and 1 more · For: Colitis, Ulcerative
Sites: Ypsilanti, Michigan; New York, New York; Asheville, North Carolina · 58 sites in all
- Anti-TNFα Use During Elective Foot and Ankle Surgery in Patients With Rheumatoid ArthritisPivotal-lookingStatus unknown
CHU de Quebec-Universite LavalAcademic, hospital or other
NCT02242474 · 660 participants (planned) · Start Jul 2015 · Primary completion Oct 2019
Drug: Anti-TNF suspended perioperatively; Anti-TNFα continued perioperatively · For: Rheumatoid Arthritis
Sites: Québec, Canada
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis.
Kerschbaumer A, Smolen JS, Ferreira RJO, et al. · Ann Rheum Dis 2024 · Systematic Review
- Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial.
Feagan BG, Sands BE, Sandborn WJ, et al. · Lancet Gastroenterol Hepatol 2023 · Randomized Controlled Trial, Clinical Trial, Phase II
- Efficacy of Biologic Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease: A Systematic Review and an Individual-Patient Data Meta-Analysis of Randomized Controlled Trials.
Ben-Horin S, Novack L, Mao R, et al. · Gastroenterology 2022 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis.
Lasa JS, Olivera PA, Danese S, et al. · Lancet Gastroenterol Hepatol 2022 · Systematic Review, Network Meta-Analysis
- Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.
Sandborn WJ, Feagan BG, Marano C, et al. · Gastroenterology 2014 · Clinical Trial, Phase II, Clinical Trial, Phase III
- Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis.
Webers C, Ortolan A, Sepriano A, et al. · Ann Rheum Dis 2023 · Systematic Review, Research Support, Non-U.S. Gov't
Sponsor: Accord Biopharma Inc. · Also marketed as Immgolis Intri
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.